| http://www.w3.org/ns/prov#value | - us 2.9%, relative risk ivabradine/placebo 1.18, p=0.018), but not in the subgroup of the overall angina population in CCS class ??? I (n=14286) (relative risk ivabradine/placebo 1.11, p=0.110).The higher than approved dose used in the study did not fully explain these findings.The SHIFT study was a large multicentre, international, randomised double-blind placebo controlled outcome trial conducted
|
